Kornimate/medical-research-clean huggingface dataset:
imatinib mesylate and zoledronic acid in patients with chronic myeloid leukaemia in cytogenetic response without molecular response

Conditions: Myeloid Leukemia, Chronic

Summary: imatinib mesylate is standard treatment of chronic myeloid leukaemia, complete cytogenetic response is obtained in most of cases but molecular response concerned only a small part of the patients. to increase molecular response ratio we decided to increase imatinib dose to limited resistance to this drug and to add zoledronate for it anti tumoral activity to increase anti leukemic effect. we plan to accrue 37 patients in 5 centers. we will analyse molecular expression of bcr-abl transcript after 6 months of treatment, safety, duration of response, vegf expression and ltgd production.


Eligibility criteria:
inclusion criteria: * inclusion criteria: at registration· chronic myeloid leukaemia ph+ confirmed by cytogenetic analysis or bcr-abl translocation by molecular biology· chronic phase:-\ 100.000 platelets· without extra medullar attempt excepted hepatosplenomagalia· first line of treatment· biology and biochemistry with normal levels· male or female\>18 years old· signed written consent· ecog\<3at inclusion· chronic myeloid leukaemia with cytogenetic response without molecular response after one year of treatment by imatinib and bcr-abl transcript detected by rt-pcr exclusion criteria: * · other cancer excepted basocellular or cervix carcinoma · major surgery in last 2 weeks previous inclusion· women who are pregnant or breastfeeding (are unable to use an acceptable method to avoid pregnancy of his partner for the entire study period)· dementia or altered mental status that would prohibit the understanding or rendering of informed consent · abnormal renal function with creatinine clearance \< 30 ml/ minuteaccording to cockcroft-gault : crcl= \[\[140-age (years)\] x weight (kg)\]/ \[72 x serum creatinine (mg/dl)\] {x 0.85 for women}· chronic myeloid leukaemia in acute phase or in pass to be in acute phase · treatment with bisphosphonates in last 6 months previous inclusion · intolerance to bisphosphonates: hypersensitivity, on course dental problem, including tooth or mandibular infection; dental traumatism or recent diagnosis or previous mandibular osteonecrosis, or dental extraction with cicatrisation delay or necessity to set bone evidence · mandibular surgery in last 6 weeks or planned in the future during treatment (tooth extraction)· serious uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy: diabetes, thyroid pathology, neuropsychiatric illness, myocardial infarction or congestive heart failure grade 3-4 according to " new york heart association"· history of psychiatric or depressive pathology · hiv positivity known · inclusion in other study investigating antineoplastic molecule in last 30 days previous inclusion

Keywords: chronic myeloid leukemia imatinib mesylate zoledronate molecular response
persistence of airway inflammation and remodeling in subjects with symptomatic or complete asthma remission

Conditions: Asthma

Summary: this study aims at determining the patterns of asthma remission, the prevalence of these different patterns, the various factors associated with such remissions and possible recurrences of asthma, in order to determine the mechanisms involved in these processes. the investigators therefore want to document these specificities in subjects in complete remission of their asthma, and those in only symptomatic remission of their asthma, in comparison with mildly symptomatic asthmatic subjects and healthy controls.

primary outcome measures : * airway inflammation (% induced sputum eosinophils) secondary outcome measures: * perception of induced respiratory symptoms * airway response to methacholine and amp, and perception scores * diurnal variation in peak expiratory flows * profile of regulatory t cells in the peripheral blood * changes in these parameters over time (baseline, 6 months, 1 and 2 years)

Eligibility criteria:
inclusion criteria: * in remission of their asthma: absence of respiratory symptoms, no rescue asthma medication need and (for complete remission) an optimal pulmonary function (fev1 \> 90%) and normal pc20 methacholine for more than two years (with no current treatment). * with a proven past history of asthma from medical files (reversible airway obstruction (\> 12% fev1 after bronchodilator or 20% by other means) proven by spirometry, pef measures or methacholine challenge according to current criteria + previous symptoms and asthma medication use), having no more asthma symptoms and not having used asthma medication for more than 2 years. * agree to sign the consent form. * no other condition that could interfere with the study measurements. exclusion criteria: * unable to adhere to the protocol requirements. * other current respiratory disease. * upper or lower respiratory tract infection or use of antibiotics \< 1 month. * use of oral corticosteroids within the last 3 months. * signs or symptoms of progressive or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurologic, or cerebral disease.

Keywords: remission of asthma
nonopioid analgesia after rotator cuff repair

Conditions: Rotator Cuff Tear

Summary: this is a randomized, single blinded, standard of care controlled clinical trial. this project aims to compare postoperative pain control in patients in two treatment arms of rotator cuff repair: a treatment group given a nonopioid pain control regimen, and a standard of care control group given standard opioid pain control regimen

study design: this is a randomized, single blinded, standard of care-controlled clinical trial. all adult patients over eighteen desiring rotator cuff repair will be eligible. nonnarcotic postoperative pain control regimen described below were chosen based on previous studies in fracture care and joint arthroplasty. patients will be consented and recruited. once participation has been determined and consent obtained, the names of participating patients will be provided to the research pharmacy. patients will be randomized with a computer-generated table in 2 patient blocks by the research pharmacy. patients postoperative analgesia will be divided into one of the following 2 treatment arms: 1) a novel nonopioid pain protocol or 2) traditional narcotic pain analgesia primary endpoints is reduction in pain as measured by visual analogue scale and patient-reported outcomes measurement information system. the endpoints will be collected at each post-operative day using a journal. moreover, endpoints will be collected at the patient's first post-operative appointment. these appointments are scheduled within one-week of the index procedure. statistical analysis: all continuous data will be analyzed using independent 2-group t tests and reported as means ± standard deviations. categorical data will be compared between the 2 groups using chi-square tests and reported as counts and percentages. a preliminary test to confirm the quality of variances will be conducted prior to utilizing the t test to confirm the appropriate statistical analysis. nonparametric equivalents wilcoxon rank-sum and fisher exact tests will be used as needed for nonnormal distributions and low variable numbers, respectively. a multivariable regression analysis was performed to assess for potential confounding demographic variables.

Eligibility criteria:
inclusion criteria: * all adult patients over age 18 and scheduled for a primary or revision rotator cuff repair exclusion criteria: * exclusion criteria will include patients with a medical history of known allergies or intolerance to allergies or intolerance to celebrex, tylenol, neurontin, dexamethasone, tramadol, substantial alcohol or drug abuse, and pregnancy, history of narcotics within 6 months of surgery, renal impairment, peptic ulcer disease, gi bleeding. secondary exclusion criterion is an intact rotator cuff
healing potentiality of blood clot s-prf and a-prf in the treatment of necrotic mature single-rooted teeth with chronic peri-apical periodontitis

Conditions: Necrotic Pulp

Summary: earlier, it was believed that successful regeneration cannot be achieved once tooth has become infected. however, recent studies suggest that regenerative endodontics may in fact be possible in teeth with pulpal necrosis and periapical pathology. the primary goal in regenerative procedure is to eliminate clinical symptoms and resolve apical periodontitis. the blood clot acts as a scaffold, and the growth factors inside recruit stem cells, most likely from periapical papilla. but unfortunately, the erythrocytes in the clot of the blood column undergo necrosis, affecting its properties so the blood column is augmented by the use of different types of scaffolds. platelet-rich fibrin is classified into four types (standard prf, injectable prf, advanced prf and concentrated growth factor cgf) according to speed and time of centrifuge with the overall aim to increase the number of platelets and leucocytes


Eligibility criteria:
inclusion criteria: * medically free patients who accept to participate in the study. * age between 18-35 years old with no sex predilection. * patients with good oral hygiene. * patients with necrotic pulp in mandibular \& maxillary single rooted permanent teeth with mature apex that symptomatic or asymptomatic , doesn't respond positively with the electric pulp tester ,associated with or without swelling /sinus tract, has radiographic evidence of periapical radiolucency, has a straight, non-curved root, teeth with normal occlusal contact with the opposing teeth. exclusion criteria: * illiterate patient because they can't estimate the pain level on the pain scale (nrs). * patients with systemic diseases or on systemic corticosteroids therapy because they have impaired healing and higher incidence of pain. * pregnant women to avoid radiation exposure during the treatment which may be hazardous to the fetus and breasts from dental x-ray examinations shields. * patients that have allergy to ciprofloxacin or metronidazole to avoid any allergic reaction after placement of bi-antibiotic paste as intra-canal medication. * patients reporting bruxism or clenching because this induce more pressure on teeth and may initiate the post-operative pain in the treated tooth which is already have peri-apical inflammation * teeth that, have vertical root fracture, coronal perforation, and calcification, are indicated for retreatment because they have lower success rate , have pocket depth greater than 5mm,need periodontal therapy , non restorable , hopeless tooth, patients that have t.m.j disorder

Keywords: regeneration . necrotic . mature teeth . blood clot . prf
chemotherapy for patients with osteosarcoma

Conditions: Osteosarcoma

Summary: the primary purpose of your participation in this study is to help answer the following research questions, and not to provide you treatment for your condition. * to assess how well treatment with pemetrexed works for patients with your type of cancer * to assess for any side effects that might be associated with pemetrexed. * to look at the characteristics and levels of certain of your genes and proteins to learn more about osteosarcoma and how pemetrexed works in your body.


Eligibility criteria:
inclusion criteria: * histological diagnosis of high grade locally advanced or metastatic osteosarcoma * must have one prior chemotherapy regimen for advanced disease * at least 1 unidimensional measurable lesion by computed tomography (ct) scan * have a good performance status * adequate organ function exclusion criteria: * have a serious concomitant systemic disorder (for example active human immunodeficiency virus infection) * have brain metastases not adequately treated * significant weight loss (that is more than 20%) over the previous 6 weeks before study entry * inability or unwillingness to take folic acid or vitamin b12 supplementation and corticosteroids * pregnant or breast-feeding
heart failure identification in a high risk cardiovascular outpatient population (hide)

Conditions: Heart Failure

Summary: this is a pilot, multicenter, real-world, single-visit, low risk, phase iv interventional study to efficiently identify new cases of heart failure (hf) stage c in subjects who are at risk of cardiovascular (cv) disease in high-volume ambulatory primary care settings in 3 countries in central america.

subjects with 2 or more cv risk factors will be identified and will undergo an nyha score assessment. if the nyha score is ≥ ii, the serum nt-probnp concentration will be determined on-site on the same day. if the serum nt probnp concentration is ≥ 125 pg/ml, the subject will be referred to a country specific central echocardiography laboratory for a transthoracic echocardiogram to measure the left ventricular ejection fraction (lvef) and relevant structural heart disease.

Eligibility criteria:
inclusion criteria: 1. signed informed consent must be obtained prior to participation in the study 2. male or female patients aged \> 60 years at the time of informed consent 3. presence of at least 2 or more of the following risk factors for hf (cv risk factors already diagnosed prior to study visit according to the usual medical practice criteria and listed in the medical chart): 1. hypertension 2. dyslipidemia 3. obesity 4. vascular disease, including coronary artery disease, cerebrovascular disease, and peripheral vascular disease 5. type 1 or 2 diabetes mellitus 6. chronic kidney disease 7. arrhythmia requiring therapy 8. moderate to severe valvular disease 9. history of alcohol abuse, 10. history of smoking, 11. history of cancer chemotherapy, or i. history of thoracic radiotherapy l. abnormal findings in the most recent ecg or m. abnormal findings in the most recent thoracic x-ray 4. attendance at a primary care consultation for reasons not related to hf exclusion criteria: 1. previous diagnosis of hf 2. diagnosis of terminal cancer (malignant tumor that may cause the subject's death in a short period: days, weeks, or a few months) 3. echocardiogram performed within the 12 months before the primary care consultation

Keywords: heart failure cardiovascular risk factors nt-probnp nyha assessment
the effects of wild blueberries on depressive symptoms in young adults

Conditions: Depression; Anxiety; Anhedonia

Summary: this study aims to investigate the effects of a 6-week dietary intervention of 22 g freeze-dried whole wild blueberry powder. the outcomes include measures of depression, anxiety, anhedonia, cognitive function, and biomarkers of inflammation and oxidative stress.

a randomized, double-blind, placebo-controlled, parallel-design study assessing the effects of a 6-week intervention of wild blueberry powder in young adults with depressive symptoms. a total of 60 participants will be randomly assigned to either 22 g blueberry powder or a matched placebo powder consumed daily with water. the severity of depression, anxiety, anhedonia, perceived stress, and quality of life will be measured at baseline and 6 weeks later. in addition, we will assess changes in cognitive function and transient mood 2 hours after consuming a single dose of blueberries.

Eligibility criteria:
inclusion criteria: * 18 to 24 years of age * patient health questionnaire-9 score ≥ 10 and a score ≥ 2 on the sum of items 1 and 2 * willingness to provide blood samples exclusion criteria: * any medically significant condition (e.g. diabetes, endocrine or gastrointestinal disorders) * taking medication (excluding hormonal contraception) * history of mental illness (excluding anxiety and unipolar depressive disorders) * allergy to blueberries or any other vaccinium species * receiving psychotherapy or counselling

Keywords: blueberry anthocyanins
migraine treatment in ed

Conditions: Migraine

Summary: randomized pilot feasibility study evaluating the impact of introducing behavioral treatment for migraine in the emergency department (ed) and prescribing migraine preventive medications in the ed. the study will examine the effect of these treatments, both individually and in combination, on pain severity and headache-related disability. this study is designed to examine the feasibility of comparing four interventions for ed patients presenting with migraine. group 1: starting topiramate; group 2: doing a brief behavioral intervention; group 3: treating with combination therapy of topiramate and behavioral intervention; and group 4: standard of care.


Eligibility criteria:
inclusion criteria: * age 18 years to 65 years of age * primary diagnosis of migraine based on the international classification of headache disorders 3 beta criteria * having a migraine 3 or more days/month. exclusion criteria: * cognitive behavioral therapy (cbt), biofeedback or other relaxation therapy in the past year * being on medication used for migraine prevention (topiramate, propranolol, valproic acid, amitriptyline/nortriptyline/imipramine/desipramine, botulinum toxin, a snri, angiotensin-converting enzyme inhibitors (ace-i) or arb) * cognitive deficit or other physical problem with the potential to interfere with behavioral therapy * substance or alcohol abuse as determined by self-report or prior documentation in the medical record.

Keywords: migraine topiramate
effects of a nutraceutical preparation on cognitive impairment in hypertensive patients

Conditions: Hypertension

Summary: aim of this randomized, double-blind clinical study is to evaluate the efficacy of a nutraceutical preparation on early markers of cognitive impairment, in patients affected by arterial hypertension.


Eligibility criteria:
inclusion criteria: * written informed consent; * males or females between 40 and 65 years of age; * hypertensive patients classified according to their sbp (systolic blood pressure) and dbp (diastolic blood pressure) values. included patients will be those with stage 1 hypertension (sbp 140-159 mmhg; dbp 90-99 mmhg) and with stage 2 hypertension (sbp 160-179 mmhg; dbp 100-109 mmhg). exclusion criteria: * previous acute myocardial infarction (ami); * previous stroke and/or transient ischemic attack (tia); * diabetes mellitus; * history of atrial fibrillation or other severe arrhythmias; * severe cardiovascular diseases; * renal pathologies (creatinine \> 1.4 mg/dl); * preexisting psychiatric pathologies; * neurodegenerative diseases, such as multiple sclerosis, lateral amyotrophic sclerosis, parkinson, alzheimer, neuromuscular pathologies, epilepsy; * diagnosis of dementia; * depression; * long-term regular use of anxiolytics drugs, antidepressant drugs, antipsychotic drugs, hypnoinducing drugs, cognitive stimulators.
safety, tolerability and efficacy of isis-gcgrrx in patients with type 2 diabetes

Conditions: Type 2 Diabetes

Summary: the purpose of this study is to evaluate the efficacy, safety, and tolerability of isis-gcgrrx in combination with metformin versus placebo


Eligibility criteria:
inclusion criteria: * male or female, age 18 to 75 * bmi ≥ 25.0 kg/m2 * hba1c ≥ 8.0% and ≤ 10.5% * type 2 diabetes mellitus and on stable dose of metformin * agree to conduct home-based (fasted) blood glucose testing as directed exclusion criteria: * clinically significant abnormalities in medical history of physical exam * show evidence of uncorrected hypothyroidism or hyperthyroidism hormone results * history of solid organ transplant or renal dialysis * history of liver disease * history of greater than 3 episodes of severe hypoglycemia within 6 months of screening * treatment with any other antidiabetic drug(s) other than metformin within 3 months of screening * history of diabetic ketoacidosis * any other significant illness or condition that may interfere with the patient participating or completing the study * inability or unwillingness to comply with protocol or study procedures
histopathologic changes in dental follicle associated with radiographically normal impacted lower third molars

Conditions: Follicle Cyst; Teeth, Impacted; Pathology

Summary: this study aimed to evaluate the incidence of histopathologic changes in dental follicles associated with radiographically normal impacted lower third molar and to determine the relationship between cystic changes in follicle tissues and age, gender, and the angular position of the impacted tooth.

patients one hundred one healthy patients whose iltm were extracted for various reasons in tokat gaziosmanpaşa university, faculty of dentistry, department of oral and maxillofacial surgery were included in the study. all participants included in the study signed an informed consent form. the study was conducted in accordance with the declaration of helsinki, and the protocol was approved by tokat gaziosmanpaşa university clinical research ethics committee for the study (project number: 19-kaek-081). the patients' panoramic radiographs were examined, and the impacted teeth were divided into four groups as vertical, horizontal, mesioangular, and distoangular according to their angular positions. the radiographically found that patients with a follicular width of less than 2.5 mm were included in the study. the follicular tissues were also excised after tooth extraction. soft tissue samples taken during surgical removal of iltm were evaluated in the department of pathology. histopathological evaluation the excision materials obtained for the study were subjected to routine tissue follow-up procedures in tokat gaziosmanpaşa university, faculty of medicine, pathology department. the samples were fixed in 10% formalin solution for 24 hours for light microscope examination and blocked using the routine paraffin blocking method. the preparations were prepared by obtaining sections with microtome from the blocks. these preparations were stained with hematoxylin eosin and evaluated under a light microscope. in the histopathological examination, squamous epithelium, keratinization, odontogenic epithelial residue, and fibrosis were evaluated as either present or absent, and inflammation was scored as 0-absent, 1-mild, 2-moderate, or 3-severe. during the microscopic evaluation of follicular tissues, soft tissue samples with stratified squamous epithelium were identified as cystic. the relationship between histopathological changes observed in the radiographically normal dental follicles and gender and the teeth' angular positions was statistically evaluated.

Eligibility criteria:
inclusion criteria: the radiographically found that patients with a follicular width of less than 2.5 mm were included in the study exclusion criteria: individuals with systemic disease